目的:对比观察25G+与27G+微创玻璃体切割手术(MIVS)治疗玻璃体视网膜疾病的疗效分析。方法:回顾性病例对照研究,选取自2018-12/2020-01期间在我院治疗的各种玻璃体视网膜疾病的患者76例76眼,随机分为25G+组和27G+组进行玻璃体切割手术治...目的:对比观察25G+与27G+微创玻璃体切割手术(MIVS)治疗玻璃体视网膜疾病的疗效分析。方法:回顾性病例对照研究,选取自2018-12/2020-01期间在我院治疗的各种玻璃体视网膜疾病的患者76例76眼,随机分为25G+组和27G+组进行玻璃体切割手术治疗,对比分析两组患者的手术时间,以及术前1d,术后1d,1、4、12、24wk的ETDRS视力、眼压、结膜水肿等变化情况。结果:相对于25G+组,27G+组玻璃体切割时间较长(27.17±5.95 vs 26.71±5.93min),而总的手术时间较短(28.26±6.88 vs 30.37±6.68min),但两组间均无差异(t=0.322,P=0.748;t=-1.353,P=0.180)。两组玻璃体切割术后,视力较术前均有明显提高,但两组间比较无差异(P>0.05)。相对于25G+组,27G+组术后1d(12.58±2.44 vs 10.56±3.21mmHg,t=2.943,P=0.004)和术后1wk(13.48±2.85 vs 12.89±2.01mmHg,t=1.460,P=0.031)的眼压波动范围较低。术后1wk内,25G+组发生一过性低眼压7眼,而在27G+组无低眼压发生,表明27G+MIVS能够更好地稳定术后眼压。结论:27G+MIVS和25G+MIVS治疗玻璃体视网膜疾病安全有效。与25G+MIVS相比,27G+MIVS术后更能够很好地稳定眼压,减少因术后低眼压引起的并发症的发生。展开更多
Purpose: Macrophages are versatile cells and have been known as a cellular component of epiretinal membranes of proliferative intraocular disorders (PID). However, the origin and functions of these cells in the membra...Purpose: Macrophages are versatile cells and have been known as a cellular component of epiretinal membranes of proliferative intraocular disorders (PID). However, the origin and functions of these cells in the membranes are not yet clear. In the present study we investigated the characterization of macrophages/monocytes in various types of human epiretinal membranes from patients with proliferative vitreortinopathy (PVR) , proliferative diabetic retinopathy (PDR) and ocular perforating injury by means of immunohistochemical techniques. Methods: A total of 49 epiretinal membranes of PID in which 24 were PDR specimens, 17 were PVR and 8 were proliferations after perforating eye injury were studied. Monoclonal antibodies against human macrophages, monocytes, HLA-DR antigen and interleukin-1 (IL-1) were used. The alkaline phosphatase anti-alkaline phosphatase (APAAP) technique was performed.Results: The results showed that 19 out of 24 PDR specimens (79%), 15 out of 17 PVR specimens (88%) and 7 out of 8展开更多
文摘目的:对比观察25G+与27G+微创玻璃体切割手术(MIVS)治疗玻璃体视网膜疾病的疗效分析。方法:回顾性病例对照研究,选取自2018-12/2020-01期间在我院治疗的各种玻璃体视网膜疾病的患者76例76眼,随机分为25G+组和27G+组进行玻璃体切割手术治疗,对比分析两组患者的手术时间,以及术前1d,术后1d,1、4、12、24wk的ETDRS视力、眼压、结膜水肿等变化情况。结果:相对于25G+组,27G+组玻璃体切割时间较长(27.17±5.95 vs 26.71±5.93min),而总的手术时间较短(28.26±6.88 vs 30.37±6.68min),但两组间均无差异(t=0.322,P=0.748;t=-1.353,P=0.180)。两组玻璃体切割术后,视力较术前均有明显提高,但两组间比较无差异(P>0.05)。相对于25G+组,27G+组术后1d(12.58±2.44 vs 10.56±3.21mmHg,t=2.943,P=0.004)和术后1wk(13.48±2.85 vs 12.89±2.01mmHg,t=1.460,P=0.031)的眼压波动范围较低。术后1wk内,25G+组发生一过性低眼压7眼,而在27G+组无低眼压发生,表明27G+MIVS能够更好地稳定术后眼压。结论:27G+MIVS和25G+MIVS治疗玻璃体视网膜疾病安全有效。与25G+MIVS相比,27G+MIVS术后更能够很好地稳定眼压,减少因术后低眼压引起的并发症的发生。
文摘Purpose: Macrophages are versatile cells and have been known as a cellular component of epiretinal membranes of proliferative intraocular disorders (PID). However, the origin and functions of these cells in the membranes are not yet clear. In the present study we investigated the characterization of macrophages/monocytes in various types of human epiretinal membranes from patients with proliferative vitreortinopathy (PVR) , proliferative diabetic retinopathy (PDR) and ocular perforating injury by means of immunohistochemical techniques. Methods: A total of 49 epiretinal membranes of PID in which 24 were PDR specimens, 17 were PVR and 8 were proliferations after perforating eye injury were studied. Monoclonal antibodies against human macrophages, monocytes, HLA-DR antigen and interleukin-1 (IL-1) were used. The alkaline phosphatase anti-alkaline phosphatase (APAAP) technique was performed.Results: The results showed that 19 out of 24 PDR specimens (79%), 15 out of 17 PVR specimens (88%) and 7 out of 8
